Dashboard
/
Keytruda (pembrolizumab)
Keytruda
EU Data — Pending your review and validation
Remaining 11 days
Data review
Please review the data captured. Data has been pre-filled by EFPIA, using publicly available data from the EMA and JCA report. If you identify any inaccuracies or have additional information to provide, please leave a comment, including the suggested update and supporting rationale.
Product name (Branded)
The trade name under which the product is marketed for EMA
Keytruda
Product name (INN)
The International Nonproprietary Name of the active substance
pembrolizumab
Therapy area
The therapy area listed by the EMA
Oncology
Orphan drug designation
Indicate whether the product has EU orphan designation
No
ATMP
Indicate whether the product is classed as an Advanced Therapy Medicinal Product (ATMP) according to the EMA
Yes
Comments
Marie Dupont added a comment
The product name (INN) is “pembrolizumab”
John Doe added a comment
The therapy area listed differs from our internal records — please confirm this is from the EMA filing.
Add a new comment
